HEALTHYWAY INC(02587) intends to sell 51% of the equity of Fujian Jianchen Medicine Co., Ltd.

HEALTHYWAY INC (02587) announced that on December 24, 2025, the company's wholly-owned subsidiary Zhejiang HEALTHYWAY INC Technology Group Co., Ltd. intends to sell 51% of the equity of Fujian Jianchen Pharmaceutical Co., Ltd. to Ms. Xiao Jing, for a total consideration of RMB 1.6779 million. The main activities of the company being sold are wholesale of drugs, operation of third-class medical devices, sales of first-class medical devices, and sales of second-class medical devices. The company being sold experienced a temporary increase in income during the outbreak of the flu epidemic at the end of 2023 due to hoarding of oseltamivir phosphate. With the decline of the epidemic, the limitations of the company being sold as a drug wholesaler with a single product inventory became apparent. Since August 2024, the drugs purchased under the purchase agreements with other pharmaceutical companies failed to generate the expected performance, resulting in a significant decrease in revenue and net profit. Given the relatively high fixed costs of drug procurement, storage, transportation, and employee salaries, and the underperformance of the operations, the group has decided to sell its equity in the company being sold to reduce costs and increase efficiency. The company intends to use the proceeds from the sale to develop the group's enterprise services and digital marketing services.